Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.

BACKGROUND Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs. RESULTS AND CONCLUSIONS Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.